Coraxan (ivabradine) coated tablets 5 mg. №56

$56.00

Manufacturer: France

Purpose: Lowers heart rate to treat stable angina by inhibiting pacemaker current.

SKU: MED57439 Category:

Description

Coraxan (ivabradine) Coated Tablets 5 mg. №56

Ingredients:

Each coated tablet contains 5 mg of ivabradine.

Dosage:

The recommended dosage is one tablet twice daily. It is important to follow the instructions provided by your healthcare provider.

Indications:

Coraxan (ivabradine) is indicated for the treatment of chronic heart failure in adults with a heart rate of 75 beats per minute or more.

Contraindications:

Do not take Coraxan if you have severe liver problems, low blood pressure, or if you are pregnant or breastfeeding. Always consult with your doctor before starting any new medication.

Directions:

Swallow the tablet whole with a glass of water, with or without food. Do not crush or chew the tablet.

Scientific Evidence:

Coraxan (ivabradine) has been extensively studied in clinical trials for its efficacy in reducing heart rate and improving outcomes in patients with chronic heart failure. A study published in the European Heart Journal demonstrated that ivabradine significantly reduced the risk of cardiovascular events in patients with heart failure.

Additional Information:

It is important to regularly monitor your heart rate and blood pressure while taking Coraxan. Contact your healthcare provider immediately if you experience any unusual symptoms or side effects.

Pharmacological Effects: Ivabradine works by selectively inhibiting the If current in the sinoatrial node, leading to a reduction in heart rate without affecting contractility or blood pressure. This mechanism of action makes it a valuable treatment option for patients with chronic heart failure.

Clinical Trials: In a multicenter, randomized controlled trial, Coraxan demonstrated a significant reduction in hospitalizations due to worsening heart failure compared to placebo. The study also showed improvements in exercise tolerance and quality of life in patients receiving ivabradine.